News
KING OF PRUSSIA, Pa., March 23, 2018 /CNW/ -- CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback